Changchun High-Tech Industries News

Tianfeng Securities released a research report on April 11 stating that it gave Changchun Hi-Tech (000661.SZ) a purchase rating. The main reasons for the rating include: 1) the growth hormone sector is progressing steadily, and new businesses are growing

Zhitong FinanceApr 11 19:05

Changchun Hi-Tech (000661): Growth hormone sector is steadily advancing research and development and continuous improvement

天風證券Apr 11 18:42

Changchun Hi-Tech (000661) 2023 Annual Report Review: The performance is in line with expectations and actively promotes the launch of new products

西部證券Apr 2 00:00

Changchun Hi-Tech (000661): Increased proportion of long-lasting water needles, steady progress in innovation and transformation

光大證券Mar 27 00:00

Changchun Hi-Tech (000661): Growth hormone is growing steadily and is ready to go in the research pipeline

西南證券Mar 22 00:00

Changchun Hi-Tech (000661) Annual Report Review Report: Long-acting Growth Hormone Releases Drive Performance Growth, Vaccine Subsidiary Creates Second Growth Pole

國盛證券Mar 20 12:41

Changchun Hi-Tech (000661): Steady growth throughout the year, new products create the second growth engine

華泰證券Mar 20 09:31

Changchun Hi-Tech (000661): Growth hormone maintains resilience and rewards shareholders with a high percentage of dividends

中泰證券Mar 20 00:00

Changchun Hi-Tech (000661): Proportion of long-acting growth hormone increases rapid release of shingles

廣發證券Mar 20 00:00

Changchun Hi-Tech (000661) Review: Growth hormone sector is growing steadily and the non-growth hormone sector is being vigorously deployed

申萬宏源研究Mar 20 00:00

Changchun Hi-Tech (000661): Steady growth in business performance, continuous improvement of R&D sector

國金證券Mar 19 00:00

Changchun Hi-Tech (000661): Released the “Double Improvement of Quality and Return” plan to improve the company's long-term investment value

德邦證券Mar 11 20:51

Changchun Hi-Tech (000661): Continuously improving the layout of the pharmaceutical industry, the “Quality and Return Double Improvement Plan” highlights confidence in long-term development

國金證券Mar 8 00:00

Changchun Gaoxin (000661): Follicle promotion injection approved for marketing, continued to enrich assisted reproduction lines

國金證券Jan 9 00:00

Changchun Hi-Tech (000661): Abundant R&D Pipelines, Strong Long-acting Growth Hormone and Vaccines with Herpes

信達證券Dec 25, 2023 16:12

Changchun Hi-Tech (000661) 2023 Third Quarter Report Review: Performance Meets Expectations, Increased Contribution of the Herpes Zoster Vaccine

西部證券Oct 26, 2023 00:00

Changchun Hi-Tech (000661) Company Incident Review Report: Growth Hormone Steady Growth and Shingles Vaccine Contributes to New Volume

華鑫證券Oct 25, 2023 11:32

Changchun Hi-Tech (000661): Performance is in line with expectations, growth hormone returns to steady growth

廣發證券Oct 25, 2023 07:46

Changchun Hi-Tech (000661): Performance is in line with expectations, growth hormone recovers season by season

中泰證券Oct 24, 2023 00:00

Changchun Hi-Tech (000661): Long-acting growth hormone continues to increase, shingles vaccine gains remarkable strength

安信證券Oct 24, 2023 00:00